Clinical Trial

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open label, multicenter Phase II clinical trial aimed at evaluating the safety and efficacy of JS207 with or without JS015 in combination with chemotherapy (XELOX) as a first-line treatment for advanced colorectal cancer with MSS/pMMR. The study was divided into two cohorts: Cohort 1 was JS207 combined with XELOX, and Cohort 2 was JS207 combined with JS015 and XELOX.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-18.
Status change: Not Yet Recruiting → Recruiting 2025-06-17
Trial Details
NCT Number NCT06885385
Lead Sponsor Shanghai Junshi Bioscience Co., Ltd.
Conditions Advanced Colorectal Cancer
Enrollment 60 participants
Start Date 2025-04-23
Primary Completion 2026-11-27 (estimated)
Study Completion 2027-02-13 (estimated)
Updated on ClinicalTrials.gov 2025-06-24